摘要
骨性关节炎(osteoarthritis,OA)是一种关节软骨破坏伴有软骨下骨肥大的缓慢进展性疾病,老年人是最常见患者,通常采用关节手术治疗。OA患者经常进行全关节置换术,关节置换的风险和高成本促使研究人员应用多潜能间充质干细胞(mesenchyma stem cells,MSCs)修复全层关节软骨。MSCs是能分化成骨、脂肪和软骨细胞的基质细胞。MSCs存在于骨髓和脂肪中,骨髓间充质干细胞(bone marrow mesenchymal stem cells,BMSCs)也可在滑膜关节中,MSCs影响OA的进展。MSCs可在体外分离和增殖,应用在临床试验中,目前的临床试验仍处于早期阶段,初步目的是评估安全性、可行性和有效性。本文综述了最近MSCs修复OA的临床试验进展。
Osteoarthritis(OA)is slow progressive disease with destruction of articular cartilage and hypertrophy of subchondral bone.The elderly are the most common patients,usually treated by joint surgery.OA patients often undergo total joint replacement.The risk and high cost of joint replacement prompt researchers to use multi-potential mesenchymal stem cells to repair full-thickness articular cartilage.Mesenchyma Stem Cells(MSCs)are stromal cells that can differentiate into bone,fat and chondrocytes.MSCs exist in bone marrow and fat.Bone Marrow Mesenchymal Stem Cells(BMSCs)can also be found in synovial joints.MSCs affect the progress of OA.MSCs can be isolated and proliferated in vitro and applied in clinical trials.Current clinical trials are still at an early stage.The primary purpose is to evaluate the safety,feasibility and effectiveness.This article reviews recent progress in clinical trials of MSCs repair of OA.
作者
崔逸爽
赵苗
滕雪峰
王茜
李琪佳
Cui Yishuang;Zhao Miao;Teng Xuefeng;Wang Qian;Li Qijia(Basic Medical College,North China University of Science and Technology,Tangshan 063000,China;Medical Laboratory Center,North China University of Science and Technology,Tangshan 063000,China)
出处
《中国综合临床》
2019年第2期187-189,共3页
Clinical Medicine of China
基金
国家科技部科技支撑课题资助项目(2012BAE06B03)
河北省科技支撑资助项目(16277776D).
关键词
间充质干细胞
骨关节炎
关节软骨
Mesenchymal stem cells
Osteoarthritis
Articular cartilage
